These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37646668)

  • 21. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
    Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A
    Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.
    Roeker LE; Knorr DA; Pessin MS; Ramanathan LV; Thompson MC; Leslie LA; Zelenetz AD; Mato AR
    Leukemia; 2020 Nov; 34(11):3047-3049. PubMed ID: 32855439
    [No Abstract]   [Full Text] [Related]  

  • 23. Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant.
    Lindahl H; Klingström J; Da Silva Rodrigues R; Christ W; Chen P; Ljunggren HG; Buggert M; Aleman S; Smith CIE; Bergman P
    J Clin Immunol; 2022 Aug; 42(6):1130-1136. PubMed ID: 35538387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.
    Goetz L; Yang J; Greene W; Zhu Y
    J Appl Lab Med; 2020 Nov; 5(6):1401-1405. PubMed ID: 32745181
    [No Abstract]   [Full Text] [Related]  

  • 25. COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.
    Langerbeins P; Fürstenau M; Gruell H; Klein F; Persigehl T; Rybniker J; Seeger-Nukpezah T; Kochanek M; Hallek M; Eichhorst B; Koehler P; Böll B
    Eur J Haematol; 2020 Oct; 105(4):508-511. PubMed ID: 32575156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma.
    Chen L; Yue J; Zhang S; Bai W; Qin L; Zhang C; Wu B; Li M; Xu S; Jiang Q; Yang L; Xu Q; Zhu R; Xie M; Gong R
    Front Immunol; 2022; 13():947724. PubMed ID: 35924252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Mellinghoff SC; Robrecht S; Mayer L; Weskamm LM; Dahlke C; Gruell H; Vanshylla K; Schlösser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
    Leukemia; 2022 Feb; 36(2):562-565. PubMed ID: 34937858
    [No Abstract]   [Full Text] [Related]  

  • 28. A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia.
    Scutari R; Fox V; De Ioris MA; Fini V; Granaglia A; Costabile V; Colagrossi L; Russo C; Mastronuzzi A; Locatelli F; Perno CF; Alteri C
    BMC Infect Dis; 2023 Mar; 23(1):133. PubMed ID: 36882724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive Immunity to Viruses: What Did We Learn from SARS-CoV-2 Infection?
    Vályi-Nagy I; Uher F; Rákóczi É; Szekanecz Z
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.
    Fiorcari S; Atene CG; Maffei R; Debbia G; Potenza L; Luppi M; Marasca R
    Haematologica; 2021 Aug; 106(8):2265-2268. PubMed ID: 33691383
    [No Abstract]   [Full Text] [Related]  

  • 32. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.
    Ju B; Zhang Q; Wang Z; Aw ZQ; Chen P; Zhou B; Wang R; Ge X; Lv Q; Cheng L; Zhang R; Wong YH; Chen H; Wang H; Shan S; Liao X; Shi X; Liu L; Chu JJH; Wang X; Zhang Z; Zhang L
    Nat Immunol; 2023 Apr; 24(4):690-699. PubMed ID: 36914890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
    Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA; Allen PB; Lechowicz MJ; Romancik JT; Ayers A; Leal A; O'Leary CB; Churnetski MC; Baird K; Kives M; Wrammert J; Nooka AK; Koff JL; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
    Cancer Res Commun; 2022 Dec; 2(12):1684-1692. PubMed ID: 36644323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.
    Guisado-Vasco P; Carralón-González MM; Aguareles-Gorines J; Martí-Ballesteros EM; Sánchez-Manzano MD; Carnevali-Ruiz D; García-Coca M; Barrena-Puertas R; de Viedma RG; Luque-Pinilla JM; Sotres-Fernandez G; Fernández-Sousa JM; Luepke-Estefan XE; López-Martín JA; Jimeno JM
    J Hematol Oncol; 2022 Jan; 15(1):4. PubMed ID: 35012608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
    Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
    Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
    Del Poeta G; Bomben R; Polesel J; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Postorino M; Laureana R; Pasqualone G; Steffan A; Gentile M; Zucchetto A; Gattei V
    Hematol Oncol; 2021 Dec; 39(5):712-714. PubMed ID: 34462939
    [No Abstract]   [Full Text] [Related]  

  • 37. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
    Niemann CU; da Cunha-Bang C; Helleberg M; Ostrowski SR; Brieghel C
    Blood; 2022 Aug; 140(5):445-450. PubMed ID: 35588468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
    Xiang T; Wang J; Zheng X
    Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.